-Reuters
Raymond James Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $33
Raymond James analyst Steven Seedhouse maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $34 to $33.